"The supply agreement with Medlab represents the first step in Aphria's International strategy. Choosing to take that step with an Australian public company, operating in the pharmaceutical space, with the resources to execute and a strategic vision consistent with Aphria's made Medlab a logical choice as Aphria's first international partner," Mr. Neufeld, Chief Executive Officer of Aphria, said. Aphria recently completed a capital raising of $34.5 million (CDN) to pursue additional expansion, a portion of which will contribute to the demand associated with this agreement.
News 
Market Data 
Discover 
